These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10455872)

  • 21. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
    Kawakami Y; Eliyahu S; Sakaguchi K; Robbins PF; Rivoltini L; Yannelli JR; Appella E; Rosenberg SA
    J Exp Med; 1994 Jul; 180(1):347-52. PubMed ID: 7516411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue.
    Clay TM; Custer MC; McKee MD; Parkhurst M; Robbins PF; Kerstann K; Wunderlich J; Rosenberg SA; Nishimura MI
    J Immunol; 1999 Feb; 162(3):1749-55. PubMed ID: 9973438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
    Cormier JN; Hijazi YM; Abati A; Fetsch P; Bettinotti M; Steinberg SM; Rosenberg SA; Marincola FM
    Int J Cancer; 1998 Feb; 75(4):517-24. PubMed ID: 9466650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells.
    Klarquist J; Barfuss A; Kandala S; Reust MJ; Braun RK; Hu J; Dilling DF; McKee MD; Boissy RE; Love RB; Nishimura MI; Le Poole IC
    Am J Pathol; 2009 Dec; 175(6):2463-72. PubMed ID: 19893037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
    Kawakami Y; Eliyahu S; Delgado CH; Robbins PF; Sakaguchi K; Appella E; Yannelli JR; Adema GJ; Miki T; Rosenberg SA
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6458-62. PubMed ID: 8022805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
    Hu Z; Xia J; Fan W; Wargo J; Yang YG
    Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
    Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of MART-1 in primary and metastatic melanoma lesions.
    Kageshita T; Kawakami Y; Hirai S; Ono T
    J Immunother; 1997 Nov; 20(6):460-5. PubMed ID: 9409451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR; Salgaller ML; Southwood S; Robbins PF; Sette A; Rosenberg SA; Kawakami Y
    J Immunol; 1996 Sep; 157(6):2539-48. PubMed ID: 8805655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.
    Jäeger E; Bernhard H; Romero P; Ringhoffer M; Arand M; Karbach J; Ilsemann C; Hagedorn M; Knuth A
    Int J Cancer; 1996 Apr; 66(2):162-9. PubMed ID: 8603805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells.
    Jantscheff P; Spagnoli G; Zajac P; Rochlitz CF
    Cancer Immunol Immunother; 2002 Sep; 51(7):367-75. PubMed ID: 12192536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look.
    Fetsch PA; Steinberg SM; Riker AI; Marincola FM; Abati A
    Cancer; 2001 Dec; 93(6):409-14. PubMed ID: 11748581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
    J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of melanosomal proteins in the immunotherapy of melanoma.
    Kawakami Y; Robbins PF; Wang RF; Parkhurst M; Kang X; Rosenberg SA
    J Immunother; 1998 Jul; 21(4):237-46. PubMed ID: 9672845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
    Meijer SL; Dols A; Jensen SM; Hu HM; Miller W; Walker E; Romero P; Fox BA; Urba WJ
    J Immunother; 2007; 30(5):533-43. PubMed ID: 17589294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.